Many overlook the importance of toxicity. Martin Welschof, CEO of BioInvent says: Toxicity is as crucial as efficacy. You can’t use what kills you.' A reminder that safety is at least as important as effectiveness in treatments. @BioInvent $BINV is one of the presenting companies at our 15th annual Healthcare Conference today. For all our BioInvent research, access our research and online trading platform (for clients): paretosec.com/updates/events…

During our 14th annual Healthcare Conference in Stockholm, we held a panel discussion featuring Fredrik Tiberg (Camurus), Renee Aguiar-Lucander (@Calliditas1), Páll Ragnar Jóhannesson (Oculis), and Martin Welschof (@BioInvent), moderated by @Frank_S_David (@pharmagellan). The panel explored the intersection between innovation, capital requirements, strategy and key success factors for #healthcare companies in an ever-changing environment. It became evident that companies who had the opportunity to raise capital in the boom year 2021 are in a better position to execute their strategy, while there was also some frustration that quality companies are not receiving the appreciation they feel they deserve in the current market environment. Overall, the healthcare industry seems to be in better shape than many believe, as the fundamentals are still in place and increasing M&A activity as well as fundraising activity from healthcare specialists indicate that the sector could have a near-term rebound. If you are interested in attending next year's conference or receiving analyst or company presentations from the event, don't hesitate to contact your Pareto Securities representative.